These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

118 related articles for article (PubMed ID: 3117539)

  • 1. In vitro activity of the new quinolone RO 23-6240 (AM-833) and the new cephalosporins RO 15-8074 and RO 19-5247 (T-2525) against Mycobacterium fortuitum and Mycobacterium chelonae.
    Hohl P; Salfinger M; Kafader FM
    Eur J Clin Microbiol; 1987 Aug; 6(4):487-8. PubMed ID: 3117539
    [No Abstract]   [Full Text] [Related]  

  • 2. The activity of the 4 quinolone Ro 23 6240 and the cephalosporins Ro 15 8074 and Ro 19 5247 against penicillin sensitive and resistant gonococci.
    Easmon CS; Woodford N; Ison CA
    J Antimicrob Chemother; 1987 Jun; 19(6):761-5. PubMed ID: 3112100
    [TBL] [Abstract][Full Text] [Related]  

  • 3. In vitro activity of ceftriaxone, cefetamet (Ro 15-8074), ceftetrame (Ro 19-5247; T-2588), and fleroxacin (Ro 23-6240; AM-833) versus Neisseria gonorrhoeae and Haemophilus ducreyi.
    Le Saux NM; Slaney LA; Plummer FA; Ronald AR; Brunham RC
    Antimicrob Agents Chemother; 1987 Jul; 31(7):1153-4. PubMed ID: 2959199
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effect of Ro 23-6240 on sensitive and resistant intracellular mycobacteria.
    Easmon C; Verity L
    Eur J Clin Microbiol; 1987 Apr; 6(2):165-6. PubMed ID: 3109896
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Activity of Ro 236240, Ro 158074 and Ro 195247 against resistant gonococci.
    Easmon CS; Woodford N; Ison CA
    Chemioterapia; 1987 Jun; 6(2 Suppl):156. PubMed ID: 3151337
    [No Abstract]   [Full Text] [Related]  

  • 6. In vitro activity of cefetamet (Ro 15-8074).
    Mittermayer H
    Eur J Clin Microbiol; 1986 Oct; 5(5):530-4. PubMed ID: 3490975
    [No Abstract]   [Full Text] [Related]  

  • 7. Antimicrobial susceptibility of five subgroups of Mycobacterium fortuitum and Mycobacterium chelonae.
    Swenson JM; Wallace RJ; Silcox VA; Thornsberry C
    Antimicrob Agents Chemother; 1985 Dec; 28(6):807-11. PubMed ID: 4083863
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Multisite reproducibility of results obtained by the broth microdilution method for susceptibility testing of Mycobacterium abscessus, Mycobacterium chelonae, and Mycobacterium fortuitum.
    Woods GL; Bergmann JS; Witebsky FG; Fahle GA; Wanger A; Boulet B; Plaunt M; Brown BA; Wallace RJ
    J Clin Microbiol; 1999 Jun; 37(6):1676-82. PubMed ID: 10325306
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Sensitivity of 7 mycobacterial species to new quinolones].
    Gevaudan MJ; Mallet MN; Gulian C; Terriou P; Lagier P; de Micco P
    Pathol Biol (Paris); 1988 May; 36(5):477-81. PubMed ID: 3136429
    [TBL] [Abstract][Full Text] [Related]  

  • 10. In-vitro activity of Ro-15-8074, a new oral cephalosporin.
    Peeters M; Piot P
    J Antimicrob Chemother; 1985 Oct; 16(4):469-73. PubMed ID: 3877719
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparative in vitro activity of cefetamet and fleroxacin against anaerobic bacteria.
    Wüst J; Hardegger U
    Eur J Clin Microbiol; 1987 Dec; 6(6):688-90. PubMed ID: 3126062
    [No Abstract]   [Full Text] [Related]  

  • 12. In vitro activities of Ro 19-5247 and Ro 15-8074, new oral cephalosporins.
    Fass RJ; Helsel VL
    Antimicrob Agents Chemother; 1986 Sep; 30(3):429-34. PubMed ID: 3777906
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparative in vitro activity of the new quinolone fleroxacin (RO 23-6240).
    Verschraegen G; Claeys G; Van den Abeele AM
    Eur J Clin Microbiol Infect Dis; 1988 Feb; 7(1):63-6. PubMed ID: 3132381
    [TBL] [Abstract][Full Text] [Related]  

  • 14. In vitro activity of Ro 15-8074, Ro 19-5247, A-56268, and roxithromycin (RU 28965) against Neisseria gonorrhoeae and Chlamydia trachomatis.
    Bowie WR; Shaw CE; Chan DG; Black WA
    Antimicrob Agents Chemother; 1987 Mar; 31(3):470-2. PubMed ID: 2953304
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Ability of ciprofloxacin but not pipemidic acid to differentiate all three biovariants of Mycobacterium fortuitum from Mycobacterium chelonae.
    Steele LC; Wallace RJ
    J Clin Microbiol; 1987 Feb; 25(2):456-7. PubMed ID: 3818939
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Preliminary study of the in vitro activity of irloxacin against mycobacteria.
    Casal M; Gutierrez J; Ruiz P; Moreno G
    Chemotherapy; 1995; 41(3):204-7. PubMed ID: 7656667
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Etest for routine clinical antimicrobial susceptibility testing of rapid-growing mycobacteria isolates.
    Koontz FP; Erwin ME; Barrett MS; Jones RN
    Diagn Microbiol Infect Dis; 1994 Jul; 19(3):183-6. PubMed ID: 7821001
    [TBL] [Abstract][Full Text] [Related]  

  • 18. In vitro activity of the two new oral cephalosporins RO 15-8074 and RO 19-5247.
    Stobberingh E; Houben AW; van Boven CP
    Eur J Clin Microbiol; 1987 Aug; 6(4):489-90. PubMed ID: 3665902
    [No Abstract]   [Full Text] [Related]  

  • 19. Treatment of nonpulmonary infections due to Mycobacterium fortuitum and Mycobacterium chelonei on the basis of in vitro susceptibilities.
    Wallace RJ; Swenson JM; Silcox VA; Bullen MG
    J Infect Dis; 1985 Sep; 152(3):500-14. PubMed ID: 3875667
    [TBL] [Abstract][Full Text] [Related]  

  • 20. In-vitro activity of fleroxacin (Ro 23-6240), a new fluoro-quinolone, and other agents, against Mycobacterium spp.
    Ernst F; van der Auwera P
    J Antimicrob Chemother; 1988 Apr; 21(4):501-4. PubMed ID: 3132443
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.